Bruker launches timsOmni mass spectrometer

Bruker (BRKR) Corporation announced the launch of the timsOmni system, a new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering deep structural insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with precise electron energy control, ion accumulation, and reaction time regulation is a cornerstone innovation of the timsOmni platform. This also enables CIU, further expanding the value of proteoform CCS information, followed by multiple electron-based and collision-based fragmentation techniques. The timsOmni uniquely enables protein researchers and biologics developers to tailor information-rich dissociation pathways for deeper insights – with high speed and high sensitivity.